Agilent Technologies, Inc. Profile Avatar - Palmy Investing

Agilent Technologies, Inc.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromat…
Medical - Diagnostics & Research
US, Santa Clara [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth 33% Weak
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q2 Δ in %
EV/EBITDA 56.26 97.13 62.16
Graham Fair Price -17.26 22.40 27.07
PEG 5636.22 -2.77 0.05
Price/Book 25.13 6.46 5.16
Price/Cash Flow 149.86 174.58 69.87
Prices/Earnings 105.15 32.59 15.89
Price/Sales 42.75 25.53 17.88
Price/FCF 149.86 174.58 69.87
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q2 Δ in %
Gross Profit Margin 0.39 0.54 0.54
Operating Margin -4.52 0.23 0.24
ROA -35.71 0.03 0.04
ROE 0.08 0.05 -39.01
ROIC 0.05 0.03 -37.82
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q2 Δ in %
Debt QOQ 0.07 -0.02 236.22
Dividends QOQ < 0.005 0.00 inf
EBIT QOQ 2.07 -0.09 -95.53
EPS QOQ 3.29 -0.12 -96.42
FCF QOQ -0.10 -0.42 -310.05
Revenue QOQ < 0.005 -0.05 435.74
Naive Interpretation member
03 - Financial Growth · Weak
Fundamentals

Leverage & Liquidity

Metric Q4 Q2 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 120.04 125.52 4.57
Days Sales Outstanding (DSO) 68.83 71.46 3.82
Inventory Turnover 0.75 0.72 -4.37
Debt/Capitalization 0.32 0.30 -4.34
Quick Ratio 1.80 1.49 -17.02
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q2 Δ in %
Book Value 20.02 21.21 5.95
Cash 5.45 5.70 4.74
Capex -0.29 -0.35 -22.20
Free Cash Flow 1.48 0.78 -46.94
Revenue 5.78 5.37 -7.13
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q2 Δ in %
Current Ratio 2.61 2.15 -17.80
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 2.27 2.88 26.58
Naive Interpretation Member
06 - Financial Health · Bad
End of A's Analysis
CIK: 1090872 CUSIP: 00846U101 ISIN: US00846U1016 LEI: - UEI: -
Secondary Listings
A has no secondary listings inside our databases.